When patients look to you for answers, look to us for insights.
Solving today’s most complex health challenges starts with putting the right data insights in the hands of the right people. At Memorial Sloan Kettering Cancer Center (MSK), we are leading the field of specialty oncology data and insights.
MSK’s robust data combines de-identified longitudinal clinical information and genomic
data from MSK’s comprehensive genomic profiling tests for both solid tumors and
hematologic malignancies. Data covers all prevalent cancer types, as well as rare cancers. Clinically relevant and actionable biomarkers are represented among the datasets.
MSK’s Clinical-Genomic data at MSK, where our record of regulatory approval includes 11-FDA approved therapies based upon MSK innovation.
To learn more about de-identified Clinico-Genomic data available for licensing from MSK, please see here.
For more information about licensing opportunities, please contact MSK’s Office of Technology Development: